Skip to main content

Kiromic Biopharma, Inc.

KRBPDelisted Nov 20, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001792581

Kiromic Biopharma, Inc. was delisted on Nov 20, 2023; its insiders filed their last Form 4 on Aug 26, 2024; no institution reported holding it in 13F filings for Q3 2023; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kiromic Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kiromic Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kiromic Biopharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Bersani PietroChief Executive Officer142,333Aug 26, 20240
Hungerford BrianChief Financial Officer64,933Aug 21, 20240
Misajon PamelaDirector28,811Jun 13, 20240
Nagel MichaelDirector43,296Jun 12, 20240
Ralston Shannon10% Owner–Jun 4, 20240
Catlin MichaelDirector25,500Mar 20, 20240
Dahlbeck ScottChief of Staff496,757Aug 15, 20220
Clark Daniel GrantChief Financial Officer62,770Aug 15, 20220
Cicchetti AmericoDirector–Jul 5, 20220
Tirelli Francis XDirector–Jul 5, 20220
Reeves KarenDirector–Jul 5, 20220
Chiriva Internati MaurizioCHIEF EXECUTIVE OFFICER1,378,072Sep 10, 20210
Ryan Michael CharlesSee Remarks50,189Aug 2, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 10, 2021 (view filing)Sep 91 dayChiriva Internati MaurizioCHIEF EXECUTIVE OFFICERPPurchase+2.80K$3.70+$10.4K+0.2%1.38M after
Jun 4, 2024 (view filing)Jun 31 dayRalston Shannon10% OwnerPPurchase+800.0K–––DerivativePrice outlier
Jun 12, 2024 (view filing)Jun 11-121 dayBersani PietroCEOPPurchase+6.00K$3.26+$19.5K+4.5%138.8K after2 lots
Jun 12, 2024 (view filing)Jun 12Same dayHungerford BrianCFOPPurchase+1.00K$3.18+$3.18K+1.8%57.9K after
Jun 12, 2024 (view filing)Jun 102 daysMisajon PamelaDirectorPPurchase+1.70K$2.93+$4.98K+6.7%27.2K after
Jun 12, 2024 (view filing)Jun 111 dayNagel MichaelDirectorPPurchase+1.00K$3.33+$3.33K+2.4%43.3K after
Jun 13, 2024 (view filing)Jun 13Same dayHungerford BrianCFOPPurchase+1.00K$2.60+$2.60K+1.7%58.9K after
Jun 13, 2024 (view filing)Jun 121 dayMisajon PamelaDirectorPPurchase+1.61K$3.28+$5.29K+5.9%28.8K after2 lots
Aug 14, 2024 (view filing)Aug 131 dayHungerford BrianChief Financial OfficerPPurchase+2.00K$1.75+$3.50K+3.4%60.9K after
Aug 21, 2024 (view filing)Aug 19-202 daysHungerford BrianChief Financial OfficerPPurchase+4.00K$2.20+$8.81K+6.6%64.9K after2 lots
Aug 26, 2024 (view filing)Aug 23-263 daysBersani PietroChief Executive OfficerPPurchase+3.49K$2.12+$7.41K+2.5%142.3K after2 lots